Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1

Rattanawong,Arkornnut; Payon,Vilawan; Limpanasittikul,Wacharee; Boonkrai,Chatikorn; Mutirangura,Apiwat; Wonganan,Piyanuch

doi:10.3892/or.2017.6084

Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1

Authors:
- Arkornnut Rattanawong
- Vilawan Payon
- Wacharee Limpanasittikul
- Chatikorn Boonkrai
- Apiwat Mutirangura
- Piyanuch Wonganan
View Affiliations

Affiliations: Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand, Systems Biology Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
Published online on: November 9, 2017 https://doi.org/10.3892/or.2017.6084
Pages: 227-238

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cepharanthine (CEP), a biscoclurine alkaloid isolated from Stephania cepharantha Hayata, has demonstrated anticancer activity in several different types of cancer cells. Colorectal cancer (CRC) is one of the most common cancers in both men and women. Mutated p53 in CRC was reported to be associated with resistance to commonly used chemotherapeutic agents including, 5‑fluorouracil, oxaliplatin and irinotecan. Many studies reported that mutation of p53 induced chemoresistance through several mechanisms, including induction of drug efflux, disruption of cell cycle regulation, evasion of apoptosis and upregulation of DNA repair. This study aimed to evaluate the anticancer activity of CEP in p53 mutant versus p53 wild-type colorectal cancer cells and determine its underlying mechanisms of action. Our results showed that CEP induced colorectal cancer cell death in a concentration-dependent manner. Remarkably, CEP was more effective in controlling the growth of the p53 mutant colorectal cancer cell lines, HT‑29 and SW-620, than the p53 wild-type colorectal cancer cell lines, COLO‑205 and HCT-116. Further studies on the underlying mechanisms revealed that CEP could induce cell cycle arrest and apoptosis in both HT‑29 and COLO‑205 cells. Treatment with CEP dramatically increased p21Waf1/Cip1 expression levels of the p53 mutant cell line HT‑29 and to a lesser extent, the p53 wild-type cell line COLO‑205. In addition, cyclin A and Bcl‑2 expression levels of both cell lines were significantly downregulated following treatment with CEP. CEP also induced ROS formation in colorectal cancer cells. Taken together, we concluded that CEP effectively induced cell cycle arrest and apoptosis which may be mediated through upregulation of p21Waf1/Cip1, downregulation of cyclin A and Bcl‑2 and induction of ROS production in colorectal cancer cells. These findings suggested that CEP could potentially be a novel anticancer agent for p53 mutant colorectal cancer cells which are often resistant to current chemotherapeutic agents.

View Figures

View References

1	O'Keefe SJ: Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol. 13:691–706. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kotelevets L, Chastre E, Desmaële D and Couvreur P: Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. Int J Pharm. 514:24–40. 2016. View Article : Google Scholar : PubMed/NCBI
3	Hu T, Li Z, Gao CY and Cho CH: Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
4	Takayama T, Miyanishi K, Hayashi T, Sato Y and Niitsu Y: Colorectal cancer: Genetics of development and metastasis. J Gastroenterol. 41:185–192. 2006. View Article : Google Scholar : PubMed/NCBI
5	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
6	He C, Li L, Guan X, Xiong L and Miao X: Mutant p53 gain of function and chemoresistance: The role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 62:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
7	Dart DA, Picksley SM, Cooper PA, Double JA and Bibby MC: The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment. Int J Oncol. 24:115–125. 2004.PubMed/NCBI
8	Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, et al: Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 64:9105–9114. 2004. View Article : Google Scholar : PubMed/NCBI
9	Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, Lesser M, Mariadason JM and Augenlicht LH: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 91:1931–1946. 2004. View Article : Google Scholar : PubMed/NCBI
10	Rogosnitzky M and Danks R: Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep. 63:337–347. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wu J, Suzuki H, Zhou YW, Liu W, Yoshihara M, Kato M, Akhand AA, Hayakawa A, Takeuchi K, Hossain K, et al: Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines. J Cell Biochem. 82:200–214. 2001. View Article : Google Scholar : PubMed/NCBI
12	Wu J, Suzuki H, Akhand AA, Zhou YW, Hossain K and Nakashima I: Modes of activation of mitogen-activated protein kinases and their roles in cepharanthine-induced apoptosis in human leukemia cells. Cell Signal. 14:509–515. 2002. View Article : Google Scholar : PubMed/NCBI
13	Harada K, Supriatno, Yamamoto S, Kawaguchi S, Yoshida H and Sato M: Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1. Anticancer Res. 23B:1441–1448. 2003.
14	Biswas KK, Tancharoen S, Sarker KP, Kawahara K, Hashiguchi T and Maruyama I: Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt. FEBS Lett. 580:703–710. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S, Kamizaki Y, Mitsuya H and Hata H: Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. Int J Oncol. 33:807–814. 2008.PubMed/NCBI
16	Seubwai W, Vaeteewoottacharn K, Hiyoshi M, Suzu S, Puapairoj A, Wongkham C, Okada S and Wongkham S: Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB. Cancer Sci. 101:1590–1595. 2010. View Article : Google Scholar : PubMed/NCBI
17	Uthaisar K, Seubwai W, Srikoon P, Vaeteewoottacharn K, Sawanyawisuth K, Okada S and Wongkham S: Cepharanthine suppresses metastatic potential of human cholangiocarcinoma cell lines. Asian Pac J Cancer Prev. 13 Suppl:149–154. 2012.PubMed/NCBI
18	Chen Z, Huang C, Yang YL, Ding Y, Ou-Yang HQ, Zhang YY and Xu M: Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells. Acta Pharmacol Sin. 33:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
19	Fang ZH, Li YJ, Chen Z, Wang JJ and Zhu LH: Inhibition of signal transducer and activator of transcription 3 and cyclooxygenase-2 is involved in radiosensitization of cepharanthine in HeLa cells. Int J Gynecol Cancer. 23:608–614. 2013. View Article : Google Scholar : PubMed/NCBI
20	Liu G, Wu D, Liang X, Yue H and Cui Y: Mechanisms and in vitro effects of cepharanthine hydrochloride: Classification analysis of the drug-induced differentially-expressed genes of human nasopharyngeal carcinoma cells. Oncol Rep. 34:2002–2010. 2015. View Article : Google Scholar : PubMed/NCBI
21	Hua P, Sun M, Zhang G, Zhang Y, Tian X, Li X, Cui R and Zhang X: Cepharanthine induces apoptosis through reactive oxygen species and mitochondrial dysfunction in human non-small-cell lung cancer cells. Biochem Biophys Res Commun. 460:136–142. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ebina T, Ishikawa K and Murata K: Antitumor effect of Cepharanthin in the double grafted tumor system. Gan To Kagaku Ryoho. 17:1165–1171. 1990.(In Japanese). PubMed/NCBI
23	Takahashi-Makise N, Suzu S, Hiyoshi M, Ohsugi T, Katano H, Umezawa K and Okada S: Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer. 125:1464–1472. 2009. View Article : Google Scholar : PubMed/NCBI
24	Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y and Ueyama Y: Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Int J Oncol. 35:1025–1035. 2009. View Article : Google Scholar : PubMed/NCBI
25	Harada K, Bando T, Yoshida H and Sato M: Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Oral Oncol. 37:643–651. 2001. View Article : Google Scholar : PubMed/NCBI
26	Bun SS, Laget M, Chea A, Bun H, Ollivier E and Elias R: Cytotoxic activity of alkaloids isolated from Stephania rotunda [corrected]. Phytother Res. 23:587–590. 2009. View Article : Google Scholar : PubMed/NCBI
27	Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
28	Fang J, Nakamura H and Iyer AK: Tumor-targeted induction of oxystress for cancer therapy. J Drug Target. 15:475–486. 2007. View Article : Google Scholar : PubMed/NCBI
29	Giaccone G and Pinedo HM: Drug Resistance. Oncologist. 1:82–87. 1996.PubMed/NCBI
30	Vazquez A, Bond EE, Levine AJ and Bond GL: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 7:979–987. 2008. View Article : Google Scholar : PubMed/NCBI
31	Hientz K, Mohr A, Bhakta-Guha D and Efferth T: The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 8:8921–8946. 2017.PubMed/NCBI
32	Pan MH, Gao JH, Lai CS, Wang YJ, Chen WM, Lo CY, Wang M, Dushenkov S and Ho CT: Antitumor activity of 3,5,4′-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog. 47:184–196. 2008. View Article : Google Scholar : PubMed/NCBI
33	Cheng TC, Lai CS, Chung MC, Kalyanam N, Majeed M, Ho CT, Ho YS and Pan MH: Potent anti-cancer effect of 3′-hydroxypterostilbene in human colon xenograft tumors. PLoS One. 9:e1118142014. View Article : Google Scholar : PubMed/NCBI
34	Ko CH, Shen SC, Lee TJ and Chen YC: Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther. 4:281–290. 2005.PubMed/NCBI
35	Wyllie F, Haughton M, Bartek J, Rowson J and Wynford-Thomas D: Mutant p53 can delay growth arrest and loss of CDK2 activity in senescing human fibroblasts without reducing p21(WAF1) expression. Exp Cell Res. 285:236–242. 2003. View Article : Google Scholar : PubMed/NCBI
36	Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
37	Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI
38	Shin SY, Ahn S, Koh D and Lim Y: p53-dependent and -independent mechanisms are involved in (E)-1-(2-hydroxyphenyl)-3-(2-methoxynaphthalen-1-yl)prop-2-en-1-one (HMP)-induced apoptosis in HCT116 colon cancer cells. Biochem Biophys Res Commun. 479:913–919. 2016. View Article : Google Scholar : PubMed/NCBI
39	Mukhtar E, Adhami VM, Khan N and Mukhtar H: Apoptosis and autophagy induction as mechanism of cancer prevention by naturally occurring dietary agents. Curr Drug Targets. 13:1831–1841. 2012. View Article : Google Scholar : PubMed/NCBI
40	Jeong JH, Kang SS, Park KK, Chang HW, Magae J and Chang YC: p53-independent induction of G1 arrest and p21Waf1/Cip1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc. Mol Cancer Ther. 9:2102–2113. 2010. View Article : Google Scholar : PubMed/NCBI
41	Aguero MF, Venero M, Brown DM, Smulson ME and Espinoza LA: Phenoxodiol inhibits growth of metastatic prostate cancer cells. Prostate. 70:1211–1221. 2010. View Article : Google Scholar : PubMed/NCBI
42	Jia L, Li H and Sun Y: Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia. 13:561–569. 2011. View Article : Google Scholar : PubMed/NCBI
43	Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, Makhtar W, Tulchinsky E, Jones GD, Roninson IB and Macip S: Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. J Biol Chem. 287:9845–9854. 2012. View Article : Google Scholar : PubMed/NCBI
44	Fitzgerald AL, Osman AA, Xie TX, Patel A, Skinner H, Sandulache V and Myers JN: Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells. Cell Death Dis. 6:e16782015. View Article : Google Scholar : PubMed/NCBI